Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SHR 2554

Next Previous
Drug Profile

SHR 2554

Alternative Names: EBI 2554; SHR-2554

Latest Information Update: 28 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Chinese PLA General Hospital; Fudan University; Jiangsu Hengrui Medicine Co.
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Enhancer of zeste homolog 2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Peripheral T-cell lymphoma
  • Phase II HER2 negative breast cancer
  • Phase I/II B-cell lymphoma; Prostate cancer; Solid tumours
  • Phase I Malignant melanoma
  • No development reported Non-Hodgkin's lymphoma; Sarcoma

Most Recent Events

  • 28 Dec 2024 No recent reports of development identified for phase-0 development in Sarcoma(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO)
  • 28 Dec 2024 No recent reports of development identified for phase-0 development in Sarcoma(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in China (PO)
  • 28 Dec 2024 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Refractory metastatic disease, Second-line therapy or greater) in China (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top